Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| BMRN - Biomarin Pharmaceutical | 16.64% | Reduce −4.6% | 1,885,811 | $103.49 | $195M | −90,454 | +$28M |
| UTHR - United Therapeutics | 14.83% | Reduce −1.3% | 625,414 | $278.09 | $174M | −8,120 | +$41M |
| FOLD - Amicus | 10.92% | Add +6.6% | 10,493,722 | $12.21 | $128M | +645,948 | +$25M |
| INSM - Insmed | 10.00% | Add +0.5% | 5,871,291 | $19.98 | $117M | +30,893 | −$8M |
| BIIB - Biogen | 8.97% | Add +5.3% | 380,082 | $276.92 | $105M | +19,101 | +$9M |
| PRTA - Prothena | 8.52% | Add +0.5% | 1,658,577 | $60.25 | $100M | +8,800 | −$97K |
| Revance Therapeutics | 8.32% | Add +19.9% | 5,283,609 | $18.46 | $98M | +878,570 | −$21M |
| Staar Surgical | 5.13% | Add +13.1% | 1,240,077 | $48.54 | $60M | +143,195 | −$17M |
| ACAD - Acadia Pharmaceuticals | 3.23% | Add +41.6% | 2,376,369 | $15.92 | $38M | +698,173 | +$10M |
| Sage Therapeutics | 2.79% | Add +0.6% | 856,517 | $38.14 | $33M | +5,108 | −$673K |
| Karyopharm Therapeutics | 1.64% | Add +0.6% | 5,655,676 | $3.40 | $19M | +34,143 | −$11M |
| ALKS - Alkermes | 1.34% | Hold | 603,400 | $26.13 | $16M | — | — |
| ALGN - Align Technology | 1.34% | Add +68.4% | 74,605 | $210.90 | $16M | +30,300 | +$7M |
| SNDX - Syndax Pharmaceuticals | 1.33% | Hold | 612,600 | $25.45 | $16M | — | — |
| ANAB - Anaptysbio | 1.14% | Hold | 431,024 | $30.99 | $13M | — | — |
| EHTH - Ehealth | 1.03% | Add +25.6% | 2,484,479 | $4.84 | $12M | +506,486 | +$4M |
| VNDA - Vanda Pharmaceuticals | 0.69% | Reduce −49.8% | 1,087,607 | $7.39 | $8M | −1,078,549 | −$13M |
| CYTK - Cytokinetics | 0.44% | Hold | 111,717 | $45.82 | $5M | — | — |
| Kezar Life Sciences | 0.39% | Hold | 656,200 | $7.04 | $5M | — | — |
| Provention Bio | 0.35% | Hold | 390,800 | $10.57 | $4M | — | — |
| TVTX - Travere Therapeutics | 0.30% | Hold | 166,069 | $21.03 | $3M | — | — |
| Gritstone Oncology | 0.20% | Reduce −71.4% | 666,127 | $3.45 | $2M | −1,664,377 | −$4M |
| Peak Bio | 0.17% | New | 497,528 | $4.06 | $2M | +497,528 | +$2M |
| MIRM - Mirum Pharmaceuticals | 0.11% | Hold | 64,700 | $19.50 | $1M | — | — |
| ALDX - Aldeyra Therapeutics | 0.10% | Hold | 160,800 | $6.96 | $1M | — | — |
| Alimera Sciences | 0.05% | Hold | 200,919 | $2.71 | $544K | — | — |
| Holding | 0.03% | Hold | 27,100 | $11.48 | $311K | — | — |
| URGN - Urogen Pharma | 0.02% | Hold | 24,500 | $8.87 | $217K | — | — |
| Gossamer Bio | 0.01% | Reduce −97.8% | 37,750 | $2.17 | $82K | −1,712,901 | −$21M |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Abiomed | 9.53% | Exit | 0 | $245.66 | $121M | −490,754 | −$121M |
| Clovis Oncology | 0.42% | Exit | 0 | $1.19 | $5M | −4,473,967 | −$5M |
| Magenta Therapeutics | 0.05% | Exit | 0 | $1.41 | $610K | −432,300 | −$610K |
| Marinus Pharmaceuticals | 0.02% | Exit | 0 | $6.64 | $208K | −31,330 | −$208K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2